MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526332 | Name: Seratrodast
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Seratrodast is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma.

Chemical Structure

Seratrodast
CAS#112665-43-7

Theoretical Analysis

MedKoo Cat#: 526332

Name: Seratrodast

CAS#: 112665-43-7

Chemical Formula: C22H26O4

Exact Mass: 354.1831

Molecular Weight: 354.45

Elemental Analysis: C, 74.55; H, 7.39; O, 18.06

Price and Availability

Size Price Availability Quantity
100mg USD 190.00
200mg USD 350.00
500mg USD 750.00
1g USD 1,250.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Seratrodast; AA2414; AA-2414; Abbott 73001; Abbott-73001; ABT 001; ABT-001; CCRIS 8939.
IUPAC/Chemical Name
(+-)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid
InChi Key
ZBVKEHDGYSLCCC-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
SMILES Code
O=C(O)CCCCCC(C(C1=O)=C(C)C(C(C)=C1C)=O)C2=CC=CC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Seratrodast blocks specific binding of U-46619 to guinea pig platelets with an IC50 value of 7.4 nM and platelet aggregation induced by U-44069 with an IC50 value of 350 nM. It is metabolized, in liver microsomes, by cytochrome P450 (CYP) isoforms 3A and 2C9/10, with a minor contribution from CYP2C8 and CYP2C19.
In vitro activity:
At clinically relevant concentrations, seratrodast inhibited tolbutamide methylhydroxylation (IC50 = 60 microM), (S)-mephenytoin 4'-hydroxylation (IC50 = 50 microM), and coumarin 7-hydroxylation (IC60 = 95 microM), indicating the potential for significant clinical interactions. Reference: Drug Metab Dispos. 1997 Jan;25(1):110-5. https://pubmed.ncbi.nlm.nih.gov/9010637/
In vivo activity:
The results of this study suggest that seratrodast might be either a ferroptosis inhibitor (IC50 = 4.5 μmol·L-1). Seratrodast could reduce lipid ROS production, regulate the system xc-/glutathione (GSH)/glutathione peroxidase 4 (GPX4) axis, and inhibit JNK phosphorylation and p53 expression. Seratrodast elevated GPX4 expression, decreased JNK phosphorylation, increased seizure latency, and reduced seizure duration in pentylenetetrazole-induced seizures in mice. Reference: Brain Res. 2022 Nov 15;1795:148073. https://pubmed.ncbi.nlm.nih.gov/36075466/
Solvent mg/mL mM comments
Solubility
DMF 50.0 141.06
DMSO 50.0 141.06
Ethanol 5.0 14.11
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 354.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Komura H, Matsushima H, Ouchi K, Shirai M, Nakazawa T, Furukawa S. Effects of antiasthma drugs on the growth of Chlamydophila pneumoniae in HEp-2 cells. J Infect Chemother. 2003 Jun;9(2):160-4. doi: 10.1007/s10156-003-0239-5. PMID: 12825116. 2. Kumar GN, Dubberke E, Rodrigues AD, Roberts E, Dennisen JF. Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5. PMID: 9010637. 3. Hao Y, Ou Y, Zhang C, Chen H, Yue H, Yang Z, Zhong X, Hu W, Sun P. Seratrodast, a thromboxane A2 receptor antagonist, inhibits neuronal ferroptosis by promoting GPX4 expression and suppressing JNK phosphorylation. Brain Res. 2022 Nov 15;1795:148073. doi: 10.1016/j.brainres.2022.148073. Epub 2022 Sep 6. PMID: 36075466. 4. Mohamed YS, Abdelsalam RM, Attia AS, Abdel-Aziz MT, El-Tanbouly DM. Regulation of liver regeneration by prostaglandin E2 and thromboxane A2 following partial hepatectomy in rats. Naunyn Schmiedebergs Arch Pharmacol. 2020 Aug;393(8):1437-1446. doi: 10.1007/s00210-020-01848-8. Epub 2020 Mar 11. PMID: 32162076.
In vitro protocol:
1. Komura H, Matsushima H, Ouchi K, Shirai M, Nakazawa T, Furukawa S. Effects of antiasthma drugs on the growth of Chlamydophila pneumoniae in HEp-2 cells. J Infect Chemother. 2003 Jun;9(2):160-4. doi: 10.1007/s10156-003-0239-5. PMID: 12825116. 2. Kumar GN, Dubberke E, Rodrigues AD, Roberts E, Dennisen JF. Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5. PMID: 9010637.
In vivo protocol:
1. Hao Y, Ou Y, Zhang C, Chen H, Yue H, Yang Z, Zhong X, Hu W, Sun P. Seratrodast, a thromboxane A2 receptor antagonist, inhibits neuronal ferroptosis by promoting GPX4 expression and suppressing JNK phosphorylation. Brain Res. 2022 Nov 15;1795:148073. doi: 10.1016/j.brainres.2022.148073. Epub 2022 Sep 6. PMID: 36075466. 2. Mohamed YS, Abdelsalam RM, Attia AS, Abdel-Aziz MT, El-Tanbouly DM. Regulation of liver regeneration by prostaglandin E2 and thromboxane A2 following partial hepatectomy in rats. Naunyn Schmiedebergs Arch Pharmacol. 2020 Aug;393(8):1437-1446. doi: 10.1007/s00210-020-01848-8. Epub 2020 Mar 11. PMID: 32162076.
1: Lou B. Crystal structure of 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxo-cyclo-hexa-1,4-dien-1-yl)hepta-noate 1,3-dihy-droxy-2-(hy-droxy-meth-yl)propan-2-aminium monohydrate: a new solid form of seratrodast. Acta Crystallogr Sect E Struct Rep Online. 2014 Sep 20;70(Pt 10):228-30. doi: 10.1107/S1600536814020625. PubMed PMID: 25484659; PubMed Central PMCID: PMC4257156. 2: Kuninobu Y, Kawata A, Noborio T, Yamamoto S, Matsuki T, Takata K, Takai K. Indium-catalyzed synthesis of keto esters from cyclic 1,3-diketones and alcohols and application to the synthesis of seratrodast. Chem Asian J. 2010 Apr 1;5(4):941-5. doi: 10.1002/asia.200900553. PubMed PMID: 20235270. 3: Xu J, Zhang Y, Hu Y. Isolation and structure elucidation of the major photodegradation products of seratrodast. J Pharm Biomed Anal. 2008 Sep 10;48(1):78-84. doi: 10.1016/j.jpba.2008.05.002. PubMed PMID: 18562149. 4: Zhang ZG, Zhang YH, Ji H, Qiu SG, Feng XC. [Design, synthesis and antiasthmatic activities of NO-donating seratrodast derivatives]. Yao Xue Xue Bao. 2004 Sep;39(9):705-10. Chinese. PubMed PMID: 15606018. 5: Fukuoka T, Miyake S, Umino T, Inase N, Tojo N, Yoshizawa Y. The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics. J Asthma. 2003 May;40(3):257-64. PubMed PMID: 12807169. 6: Urakami K, Beezer AE. A kinetic and thermodynamic study of seratrodast polymorphic transition by isothermal microcalorimetry. Int J Pharm. 2003 May 12;257(1-2):265-71. PubMed PMID: 12711181. 7: Horiguchi T, Tachikawa S, Kondo R, Shiga M, Hirose M, Fukumoto K. Study on the usefulness of seratrodast in the treatment of chronic pulmonary emphysema. Arzneimittelforschung. 2002;52(10):764-8. PubMed PMID: 12442639. 8: Muramatsu H, Kotajima R, Sato T. [Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients]. Arerugi. 2001 Jun;50(6):540-6. Japanese. PubMed PMID: 11517517. 9: Wouters J, Durant F, Masereel B. Antagonism of the TXA2 receptor by seratrodast: a structural approach. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2867-70. PubMed PMID: 10522708. 10: Terao S, Shiraishi M, Matsumoto T, Ashida Y. [Thromboxane A2 antagonist--discovery of seratrodast]. Yakugaku Zasshi. 1999 May;119(5):377-90. Review. Japanese. PubMed PMID: 10375998. 11: Ohta R, Amano T, Yamashita K, Motohashi M. High-performance liquid chromatographic determination of seratrodast and its metabolites in human serum and urine. J Chromatogr B Biomed Sci Appl. 1997 Dec 19;704(1-2):325-31. PubMed PMID: 9518166. 12: Samara E, Cao G, Locke C, Granneman GR, Dean R, Killian A. Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma. Clin Pharmacol Ther. 1997 Oct;62(4):426-35. PubMed PMID: 9357394. 13: Kumar GN, Dubberke E, Rodrigues AD, Roberts E, Dennisen JF. Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5. PubMed PMID: 9010637.